Reuters logo
BRIEF-Cormedix announced an update in ongoing U.S. Phase 3 "lock-it 100" clinical trial of its lead product candidate neutrolin - SEC Filing
2017年4月20日 / 下午1点38分 / 5 个月前

BRIEF-Cormedix announced an update in ongoing U.S. Phase 3 "lock-it 100" clinical trial of its lead product candidate neutrolin - SEC Filing

April 20 (Reuters) - Cormedix Inc

* Cormedix Inc- Announced an update in ongoing U.S. Phase 3 “lock-it 100” clinical trial of its lead product candidate neutrolin - SEC filing

* Cormedix - Has to date enrolled 368 patients in lock-it 100 clinical trial, recently completed safety review by independent data and safety monitoring board

* Cormedix - DSMB unanimously concluded it is safe to continue trial as designed based on evaluation of data from first 279 patients randomized on trial

* Cormedix Inc- Topline results expected to be available around year-end 2018 in phase 3 “lock-it 100” for neutrolin

* Cormedix Inc- Currently in discussions with FDA regarding possible prospective changes to protocol for clinical trial

* Cormedix Inc - FDA has accepted co's proposal to include one or more interim efficacy analyses of trial data while lock-it 100 is ongoing Source text: [bit.ly/2o7Dg6e] Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below